Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$281.41
-3.3%
$304.54
$253.30
$346.85
$151.17B0.592.77 million shs4.68 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$21.57
-4.1%
$25.42
$20.92
$31.54
$127.55B0.6740.15 million shs72.42 million shs
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$12.85
-9.3%
$15.95
$12.48
$22.80
$14.56B0.729.93 million shs20.53 million shs
Viatris Inc. stock logo
VTRS
Viatris
$7.26
-6.8%
$9.61
$6.86
$13.55
$8.67B0.919.66 million shs20.39 million shs
Viatris Inc. stock logo
VTRS
Viatris
$7.26
-6.8%
$9.61
$6.86
$13.55
$8.67B0.919.66 million shs20.39 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+3.86%-4.78%-11.08%+10.17%+7.67%
Pfizer Inc. stock logo
PFE
Pfizer
+3.47%-9.02%-15.49%-16.42%-15.97%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
+4.65%-7.48%-3.54%-34.12%+1.36%
Viatris Inc. stock logo
VTRS
Viatris
+5.84%-10.05%-18.00%-34.87%-34.09%
Viatris Inc. stock logo
VTRS
Viatris
+5.84%-10.05%-18.00%-34.87%-34.09%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amgen Inc. stock logo
AMGN
Amgen
4.6166 of 5 stars
3.24.03.33.93.42.50.6
Pfizer Inc. stock logo
PFE
Pfizer
4.992 of 5 stars
4.33.04.24.32.73.33.1
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.2222 of 5 stars
3.43.00.80.02.20.80.6
Viatris Inc. stock logo
VTRS
Viatris
2.3057 of 5 stars
2.93.02.50.01.71.70.6
Viatris Inc. stock logo
VTRS
Viatris
2.3057 of 5 stars
2.93.02.50.01.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.48
Hold$315.2212.01% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.59
Moderate Buy$31.0744.06% Upside
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.86
Moderate Buy$23.4382.39% Upside
Viatris Inc. stock logo
VTRS
Viatris
1.75
Reduce$10.5044.63% Upside
Viatris Inc. stock logo
VTRS
Viatris
1.75
Reduce$10.5044.63% Upside

Current Analyst Ratings Breakdown

Latest TEVA, VTRS, PFE, AMGN, and VTRS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2025
Amgen Inc. stock logo
AMGN
Amgen
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$328.00 ➝ $330.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$28.00 ➝ $24.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$32.00 ➝ $25.00
3/27/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/7/2025
Viatris Inc. stock logo
VTRS
Viatris
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $13.00
3/7/2025
Viatris Inc. stock logo
VTRS
Viatris
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $13.00
3/6/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $20.00
3/5/2025
Amgen Inc. stock logo
AMGN
Amgen
Johnson Rice
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$294.00
(Data available from 4/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$33.42B4.52$28.20 per share9.98$10.93 per share25.75
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B1.92$3.38 per share6.38$15.81 per share1.36
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$16.54B0.88$2.54 per share5.05$4.75 per share2.70
Viatris Inc. stock logo
VTRS
Viatris
$14.74B0.59$3.44 per share2.11$17.06 per share0.43
Viatris Inc. stock logo
VTRS
Viatris
$14.74B0.59$3.44 per share2.11$17.06 per share0.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$4.09B$7.5537.2713.162.6312.24%176.32%11.71%5/1/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4115.307.120.6412.62%19.47%8.09%4/29/2025 (Estimated)
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$1.45N/A4.881.44-9.91%42.46%6.65%5/7/2025 (Estimated)
Viatris Inc. stock logo
VTRS
Viatris
$54.70M-$0.53N/A2.82N/A-5.87%16.46%7.09%5/8/2025 (Estimated)
Viatris Inc. stock logo
VTRS
Viatris
$54.70M-$0.53N/A2.82N/A-5.87%16.46%7.09%5/8/2025 (Estimated)

Latest TEVA, VTRS, PFE, AMGN, and VTRS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Viatris Inc. stock logo
VTRS
Viatris
$0.52N/AN/AN/A$3.30 billionN/A
5/8/2025Q1 2025
Viatris Inc. stock logo
VTRS
Viatris
$0.52N/AN/AN/A$3.30 billionN/A
5/7/2025Q1 2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.47N/AN/AN/A$3.99 billionN/A
5/1/2025Q1 2025
Amgen Inc. stock logo
AMGN
Amgen
$4.18N/AN/AN/A$8.05 billionN/A
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67N/AN/AN/A$14.43 billionN/A
2/27/2025Q4 2024
Viatris Inc. stock logo
VTRS
Viatris
$0.57$0.54-$0.03-$0.43$3.60 billion$3.53 billion
2/27/2025Q4 2024
Viatris Inc. stock logo
VTRS
Viatris
$0.57$0.54-$0.03-$0.43$3.60 billion$3.53 billion
2/4/2025Q4 2024
Amgen Inc. stock logo
AMGN
Amgen
$5.04$5.31+$0.27$1.16$8.87 billionN/A
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
1/29/2025Q4 2024
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.69$0.70+$0.01-$0.19$4.10 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$9.523.38%+8.53%126.09%14 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.97%+2.50%121.99%16 Years
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$1.017.87%N/AN/A N/A
Viatris Inc. stock logo
VTRS
Viatris
$0.486.61%+13.30%N/A N/A
Viatris Inc. stock logo
VTRS
Viatris
$0.486.61%+13.30%N/A N/A

Latest TEVA, VTRS, PFE, AMGN, and VTRS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/4/2025
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.383.05%5/16/20255/16/20256/6/2025
2/24/2025
Viatris Inc. stock logo
VTRS
Viatris
quarterly$0.125.2%3/10/20253/10/20253/18/2025
2/24/2025
Viatris Inc. stock logo
VTRS
Viatris
quarterly$0.125.2%3/10/20253/10/20253/18/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
9.62
1.26
0.95
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.97
0.98
0.75
Viatris Inc. stock logo
VTRS
Viatris
0.82
1.51
0.96
Viatris Inc. stock logo
VTRS
Viatris
0.82
1.51
0.96

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
54.05%
Viatris Inc. stock logo
VTRS
Viatris
79.88%
Viatris Inc. stock logo
VTRS
Viatris
79.88%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.69%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.55%
Viatris Inc. stock logo
VTRS
Viatris
0.13%
Viatris Inc. stock logo
VTRS
Viatris
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
28,000537.21 million533.50 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
36,8001.13 billion1.13 billionOptionable
Viatris Inc. stock logo
VTRS
Viatris
37,0001.19 billion1.19 billionOptionable
Viatris Inc. stock logo
VTRS
Viatris
37,0001.19 billion1.19 billionOptionable

Recent News About These Companies

Medicine background - stock image
2 Generic Drug Stocks Ready to Surge in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amgen stock logo

Amgen NASDAQ:AMGN

$281.41 -9.68 (-3.33%)
Closing price 04:00 PM Eastern
Extended Trading
$283.40 +1.98 (+0.71%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Pfizer stock logo

Pfizer NYSE:PFE

$21.57 -0.92 (-4.10%)
Closing price 03:59 PM Eastern
Extended Trading
$21.60 +0.04 (+0.17%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$12.84 -1.32 (-9.29%)
Closing price 03:59 PM Eastern
Extended Trading
$12.82 -0.02 (-0.16%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Viatris stock logo

Viatris NASDAQ:VTRS

$7.26 -0.53 (-6.80%)
Closing price 04:00 PM Eastern
Extended Trading
$7.24 -0.01 (-0.21%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris stock logo

Viatris NASDAQ:VTRS

$7.26 -0.53 (-6.80%)
Closing price 04:00 PM Eastern
Extended Trading
$7.24 -0.01 (-0.21%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.